MARKET

IBIO

IBIO

Ibio
AMEX
2.560
+0.020
+0.79%
After Hours: 2.590 +0.03 +1.17% 19:58 11/08 EST
OPEN
2.510
PREV CLOSE
2.540
HIGH
2.635
LOW
2.454
VOLUME
45.75K
TURNOVER
--
52 WEEK HIGH
6.47
52 WEEK LOW
1.021
MARKET CAP
23.39M
P/E (TTM)
-0.3938
1D
5D
1M
3M
1Y
5Y
1D
Earnings week ahead: DIS, BABA, JD, CSCO, HD, OXY, SU, SHOP, AMAT, SPOT, and more
Seeking Alpha · 11h ago
Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching
Barchart · 2d ago
Weekly Report: what happened at IBIO last week (1028-1101)?
Weekly Report · 6d ago
Weekly Report: what happened at IBIO last week (1021-1025)?
Weekly Report · 10/28 09:38
iBio Unveils AI-Driven Antibody Discovery Strategy
TipRanks · 10/23 13:28
Weekly Report: what happened at IBIO last week (1014-1018)?
Weekly Report · 10/21 09:38
Weekly Report: what happened at IBIO last week (1007-1011)?
Weekly Report · 10/14 09:46
Biotech Alert: Searches spiking for these stocks today
TipRanks · 10/10 15:10
More
About IBIO
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.

Webull offers Ibio Inc stock information, including AMEX: IBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IBIO stock methods without spending real money on the virtual paper trading platform.